Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Input files: A modular, immunopeptidogenomic (iPepGen) analysis pipeline for discovery, verification, and prioritization of cancer peptide neoantigen candidates

ABSTRACT: Characterizing tumor-specific neoantigen peptides, which are derived from genomic or transcriptomic aberrations and presented to the immune system, is essential for studies in immuno-oncology. To facilitate this process, the modular iPepGen immunopeptidogenomics pipeline offers several key functions: (1) Neoantigen prediction and generation of a protein database from genomic or transcriptomic sequencing data; (2) Peptide identification; (3) Verification using immunopeptidomic mass spectral data; (4) Neoantigen classification and visualization; and (5) Candidate prioritization for further research. The pipeline is easily accessible through a publicly available, scalable cloud-based gateway and includes online interactive training materials. This streamlines adoption by cancer researchers, particularly those who may lack advanced computational expertise and resources for immunopeptidogenomic analysis.

INSTRUMENT(S): ThermoFisher Orbitrap

ORGANISM(S): Human

SUBMITTER: Timothy J.Griffin

PROVIDER: MSV000100019 | MassIVE | Tue Nov 25 12:03:00 GMT 2025

SECONDARY ACCESSION(S): PXD071206

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer

Project description:Neoantigen-reactive cytotoxic T lymphocytes play a vital role in precise cancer cell elimination. In this study, we demonstrate the effectiveness of personalized neoantigen-based T cell therapy in inducing tumor regression in two patients suffering from heavily-burdened metastatic ovarian cancer. Our approach involved the development of a robust pipeline for ex vivo expansion of neoantigen-reactive T lymphocytes. Neoantigen peptides were designed and synthesized based on the somatic mutations of the tumors and their predicted HLA binding affinities. These peptides were then presented to T lymphocytes through co-culture with neoantigen-loaded dendritic cells for ex vivo expansion. Subsequent to cell therapy, both patients exhibited significant reductions in tumor marker levels and experienced substantial tumor regression. One patient achieved repeated cancer regression through infusions of T cell products generated from newly identified neoantigens. Transcriptomic analyses revealed a remarkable increase in neoantigen-reactive cytotoxic lymphocytes in the peripheral blood of the patients following cell therapy. These cytotoxic T lymphocytes expressed polyclonal T cell receptors (TCR) against neoantigens, along with abundant cytotoxic proteins and pro-inflammatory cytokines. The efficacy of neoantigen targeting was significantly associated with the immunogenicity and TCR polyclonality. Notably, the neoantigen-specific TCR clonotypes persisted in the peripheral blood after cell therapy. Our findings indicate that personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against ovarian cancer, suggesting its promising potential in cancer immunotherapy.

2023-12-01 | GSE248401 | GEO

ilEgiCons

Project description:Egira conspicillaris (silver cloud), genomic and transcriptomic data

| PRJEB83476 | ENA

Aphrocallistes vastus

Project description:Aphrocallistes vastus (cloud sponge) genomic and transcriptomic data

| PRJNA1422750 | ENA

Proteogenomic Discovery of Neoantigens Facilitates Personalized Multi-antigen Targeted T cell Immunotherapy for Brain Tumors

Project description:Neoantigen discovery in pediatric brain tumors is hampered by their low mutational burden and scant tissue availability. We developed a low-input proteogenomic approach combining tumor DNA/RNA sequencing and mass spectrometry proteomics to identify tumor-restricted (neoantigen) peptides arising from multiple genomic aberrations to generate a highly target-specific, autologous, personalized T cell immunotherapy. Our data indicate that novel splice junctions are the primary source of neoantigens in medulloblastoma, a common pediatric brain tumor. Proteogenomically identified tumor-specific peptides are immunogenic and generate MHC II-based T cell responses. Moreover, polyclonal and polyfunctional T cells specific for tumor-specific peptides effectively eliminated tumor cells in vitro. Targeting novel tumor-specific antigens obviates the issue of central immune tolerance while potentially providing a safety margin favoring combination with other immune-activating therapies. These findings demonstrate the proteogenomic discovery of immunogenic tumor-specific peptides and lay the groundwork for personalized targeted T cell therapies for children with brain tumors.

2021-11-02 | PXD029082 | Pride

Rewiring human cellular input-output using modular extracellular sensors.

Project description:Engineered cell-based therapies comprise a promising emerging strategy for treating diverse diseases. Realizing this promise requires new tools for engineering cells to sense and respond to soluble extracellular factors, which provide information about both physiological state and the local environment. Here, we report such a biosensor engineering strategy, leveraging a self-contained receptor-signal transduction system termed modular extracellular sensor architecture (MESA). We developed MESA receptors that enable cells to sense vascular endothelial growth factor (VEGF) and, in response, secrete interleukin 2 (IL-2). By implementing these receptors in human T cells, we created a customized function not observed in nature-an immune cell that responds to a normally immunosuppressive cue (VEGF) by producing an immunostimulatory factor (IL-2). Because this platform utilizes modular, engineerable domains for ligand binding (antibodies) and output (programmable transcription factors based upon Cas9), this approach may be readily extended to novel inputs and outputs. This generalizable approach for rewiring cellular functions could enable both translational applications and fundamental biological research.

| S-EPMC11536266 | biostudies-literature

Modular use of peripheral input channels tunes motion-detecting circuitry.

Project description:In the visual system, peripheral processing circuits are often tuned to specific stimulus features. How this selectivity arises and how these circuits are organized to inform specific visual behaviors is incompletely understood. Using forward genetics and quantitative behavioral studies, we uncover an input channel to motion detecting circuitry in Drosophila. The second-order neuron L3 acts combinatorially with two previously known inputs, L1 and L2, to inform circuits specialized to detect moving light and dark edges. In vivo calcium imaging of L3, combined with neuronal silencing experiments, suggests a neural mechanism to achieve selectivity for moving dark edges. We further demonstrate that different innate behaviors, turning and forward movement, can be independently modulated by visual motion. These two behaviors make use of different combinations of input channels. Such modular use of input channels to achieve feature extraction and behavioral specialization likely represents a general principle in sensory systems.

| S-EPMC3713415 | biostudies-literature

Human colorectal cancer and wildtype LC-MSMS

Project description:This project introduces **NARWHAL**, a versatile platform and pipeline for neoantigen discovery in cancer immunotherapy. NARWHAL identifies mutated tumor-specific antigens (mTSAs) and aberrantly expressed antigens (aeTSAs) by integrating somatic mutation data, gene expression levels, and MHC binding affinity predictions. The platform’s unique k-mer profiling technique identifies aeTSAs from coding and noncoding regions, enabling comprehensive annotation. Validated with clinical data, NARWHAL advances neoantigen identification, supporting personalized cancer treatments by uncovering novel immunotherapy targets and enhancing therapeutic precision.

2026-01-28 | PXD057687 | Pride

NeoDisc: A neoantigen discovery pipeline for the development of personalized cancer immunotherapy

Project description:The accurate identification and prioritization of antigenic peptides presented by class-I and -II human leukocyte antigens (HLA-I and -II) recognized by autologous T cells is crucial for the development of cancer immunotherapies. While several clinical neoantigen prediction pipelines are now publicly available, none of them allows the direct integration of mass spectrometry immunopeptidomics data that can uncover antigenic peptides derived from various canonical and non-canonical sources. Therefore, we have developed and shared a unique ‘end-to-end’ clinical proteo-genomic pipeline, called NeoDisc. NeoDisc is a fast and modular computational pipeline that combines state-of-the-art publicly available and in-house software for genomics, transcriptomics, mass-spectrometry-based immunopeptidomics, and in silico tools for the identification, prediction, and prioritization of tumor-specific and immunogenic antigens from multiple sources. We demonstrated the application of NeoDisc for personalized antigen discovery, in the context of heterogenic antigenic landscape and defective cellular antigen presentation machineries, and we highlighted its clinical implementation.

2024-08-30 | PXD047641 | Pride

Modular, multi-input transcriptional logic gating with orthogonal LacI/GalR family chimeras.

Project description:In prokaryotes, the construction of synthetic, multi-input promoters is constrained by the number of transcription factors that can simultaneously regulate a single promoter. This fundamental engineering constraint is an obstacle to synthetic biologists because it limits the computational capacity of engineered gene circuits. Here, we demonstrate that complex multi-input transcriptional logic gating can be achieved through the use of ligand-inducible chimeric transcription factors assembled from the LacI/GalR family. These modular chimeras each contain a ligand-binding domain and a DNA-binding domain, both of which are chosen from a library of possibilities. When two or more chimeras have the same DNA-binding domain, they independently and simultaneously regulate any promoter containing the appropriate operator site. In this manner, simple transcriptional AND gating is possible through the combination of two chimeras, and multiple-input AND gating is possible with the simultaneous use of three or even four chimeras. Furthermore, we demonstrate that orthogonal DNA-binding domains and their cognate operators allow the coexpression of multiple, orthogonal AND gates. Altogether, this work provides synthetic biologists with novel, ligand-inducible logic gates and greatly expands the possibilities for engineering complex synthetic gene circuits.

| S-EPMC4210161 | biostudies-literature

Project description:Adoption Study

| PRJNA593844 | ENA